IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Discovery of New Circulating Biomarkers of Coronary Atherosclerosis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention |
|---|---|
| Coronary Artery Disease Acute Coronary Syndromes Myocardial Infarction Atherosclerosis | Procedure: per intervention |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Discovery of New Circulating Biomarkers of Coronary Atherosclerosis Using Differential Proteomics: the BIOmarkers of CORonary Events (BIOCORE) Study |
| Enrollment: | 124 |
| Study Start Date: | March 2007 |
| Study Completion Date: | November 2009 |
| Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
30 patients
|
Procedure: per intervention
per intervention
|
|
2
30 patients
|
Procedure: per intervention
per intervention
|
|
3
30 patients
|
Procedure: per intervention
per intervention
|
Detailed Description:
Hypothesis: Our hypothesis is that coronary atherosclerosis induces both quantitative and qualitative modifications of circulating proteins, which can be captured by a differential proteomic approach applied to serum or plasma samples. Identification of such modifications in the circulating blood of patients with coronary artery disease (versus patients without coronary artery disease) and/or of patients with acute coronary syndromes (versus stable coronary artery disease) may lead to discovery of new biomarkers of coronary atherosclerosis and of atherosclerotic plaque vulnerability.
Objectives:
Primary objective: Identification of new circulating biomarkers of stable and unstable coronary artery disease using a new approach of differential proteomics.
Secondary objectives:
- Evaluation of the diagnostic value of these new biomarkers for the diagnosis of stable and unstable coronary artery disease.
- Comparison of the diagnostic value of these new biomarkers to the diagnostic value of 1) other validated biomarkers of atherosclerosis (eg, CRP, IL-6, CD40L, markers of leukocyte activation, …); and 2) of non-invasive measures of arterial function (eg, carotid artery intima-media thickness, pulse wave velocity, ankle/brachial index, …)
- Description of the relationship between these new biomarkers and major adverse coronary events (death, myocardial infarction, revascularization) during a 12-month follow-up.
Methods:
Uniq center, prospective study. Three groups of patients will be studied. Group 1: Non-ST-elevation acute myocardial infarction; Group 2: Stable coronary artery disease; Group 3: normal coronary arteries and absence of other detectable atherosclerotic lesions.
A new proteomic approach will be applied to serum and plasma samples obtained 1 month after the index hospitalisation. This approach includes 3 steps: 1) equalisation of circulating proteins (expose low-concentration proteins belonging to the "deep-proteome"); 2) Retention chromatography; and 3) protein separation using 2D-electrophoresis and Surface-Enhanced Laser Desorption/Ionisation Time-of-Flight (SELDI-TOF).
Biomarkers with the highest diagnostic value will be subsequently identified using Matrix-Assisted Laser Desorbtion/Ionisation Time-of-Flight (MALDI-TOF) and tandem mass spectrometry (MS/MS).
Perspectives:
Validation of the diagnostic and prognostic values of the new biomarkers discovered and identified using the proteomic approach described above will require development of more straightforward measurement techniques (eg, ELISA), which will be used prospectively or retrospectively in other cohorts of patients with coronary artery disease. Basic studies will be performed in parallel, so as to better understand the role of these new biomarkers in the pathophysiology of atherosclerosis.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Identification de nouveaux marqueurs circulants de l'athérosclérose coronarienne et de ses complications par une nouvelle technique de protéomique différentielle.
Identification of new parqueurs circulated in coronary artheriosclerosis and complications of the new differentiel technicology
Inclusion Criteria:
-
Group 1 (Non-ST-elevation acute myocardial infarction) :
- Chest pain less than 48 hours before admission,
- And modifications of ST-T (no persistent ST elevation) on 12-lead EKG,
- And elevation of troponin-I >1xN,
- And presence of ≥1 de novo stenosis(es) >50% located on ≥1 native coronary artery(ies) and successfully treated using percutaneous coronary intervention and stenting.
-
Group 2 (Stable coronary artery disease) :
- Documented myocardial ischemia (stable angina or positive stress test)
- And presence of ≥1 de novo stenosis(es) >50% located on ≥1 native coronary artery(ies) and successfully treated using percutaneous coronary intervention and stenting.
-
Group 3 (Normal coronary arteries) :
- No history of coronary artery disease, neurovascular disease or peripheral artery disease,
- And normal coronary angiography performed because of suspected coronary artery disease
- And absence of significant functional or anatomic abnormalities suggestive of atherosclerosis on non-invasive arterial studies (measurements of intima-media thickness, pulse wave velocity, ankle-brachial index, …).
Exclusion Criteria:
-
Group 1 :
- Preexisting EKG abnormalities (including left bundle branch block) precluding accurate assessment of ST-T changes
-
Group 2 :
- History of acute coronary syndrome
-
Groups 1 and 2:
- Culprit coronary artery stenosis is a restenosis or a stent thrombosis or is located in a bypass graft.
-
All groups :
- Heart failure (NYHA class ≥II)
- Left ventricular ejection fraction <50%
- Severe valvular heart disease requiring surgical or percutaneous therapy
- History of autoimmune, inflammatory or neoplasia diseases ; or infectious disease in the month before admission
- Life expectancy < 1 year
- Age <18 years or >80 years
- Current pregnancy or breast-feeding
- Homeless or travelers who may not be followed-up
- Refusal to sign the informed consent form
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00430820
| France | |
| Department of Cardiology, Hopital Bichat, APHP | |
| Paris, France, 75018 | |
| Principal Investigator: | Laurent FELDMAN, MD,PhD | Assistance Publique - Hôpitaux de Paris |
More Information
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Yannick Vacher, Department Clinical Research of Developppement |
| ClinicalTrials.gov Identifier: | NCT00430820 History of Changes |
| Other Study ID Numbers: |
P060201 |
| Study First Received: | February 1, 2007 |
| Last Updated: | December 2, 2010 |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
Biomarkers Proteomics Mass spectrometry Atherosclerosis |
Acute coronary syndromes Myocardial infarction Coronary artery disease |
Additional relevant MeSH terms:
|
Infarction Coronary Artery Disease Myocardial Ischemia Coronary Disease Myocardial Infarction Atherosclerosis Acute Coronary Syndrome Ischemia |
Pathologic Processes Necrosis Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on July 17, 2017